Detail akcie Novartis AG online

Business Summary: Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Novartis AG revenues increased 12% to $13.59B. Net income increased 34% to $3.61B. Revenues reflect Cardiovascular, Renal and Metabolism - Entresto segment increase of 20% to $2.26B, Oncology -Kisqali segment increase of 52% to $956M, US segment increase of 24% to $5.71B, Asia / Africa / Australasia segment increase of 7% to $2.77B.